Previous 10 | Next 10 |
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial in Japan evaluating TEPEZZA for the treatment of adults with chronic Thyroid Eye Disease (TED) and low clinical activity score (CAS), which is a measure of disease activity...
2023-04-28 15:00:41 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
2023-04-26 15:53:48 ET Amgen ( NASDAQ: AMGN ) is scheduled to announce Q1 2023 financial results on Thursday, April 26, after market close. The consensus EPS estimate is $3.85 and the consensus revenue estimate is $6.18B. Over the last two years, the biotech has had ...
2023-04-23 00:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The bank tsunami that ...
2023-04-21 15:43:19 ET The deal spread in Broadcom's ( AVGO ) planned $61 billion purchase of VMware ( NYSE: VMW ) spread widened on Friday amid a new Federal Trade Commission notice for two meetings in the next few weeks. The spread widened to $2.30. The FTC listed listed t...
-- Oral presentation on the relationship between B-cell subsets and NMOSD attacks to be held on April 23 at 1:48 p.m. EDT -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that multiple UPLIZNA analyses will be presented at the 2023 American Academy of Neurology (AAN) Annua...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of the third annual global innovation challenge, The Horizon Prize, powered by MIT Solve. Each year, the Horizon Prize poses a challenge question, asking entrepreneurs and innovators worldwide to think creatively to solve a re...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS...
2023-04-14 11:26:47 ET Horizon Pharmaceuticals ( NASDAQ: HZNP ) rose 1.2% as traders circulated a date for an Irish court hearing for the approval of its sale to Amgen ( NASDAQ: AMGN ) was set for next month. An Irish court set a date of May 24 for a hearing on Horiz...
2023-04-14 08:47:02 ET Horizon Therapeutics ( NASDAQ: HZNP ) announced Friday that the FDA approved an update to the labeling information of the company's thyroid eye disease (TED) therapy Tepezza related to its indications and usage. Accordingly, the FDA has cleared Tepezza u...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...